Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Research and reviews on oral combination medications

08-28-2018 | Oral combination medications | Article

Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: A systematic review and meta-analysis

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

08-26-2018 | Oral combination medications | Article

Mechanistic insights from sequential combination therapy with an SGLT2 inhibitor and DPP‐IV inhibitor: Results from the CANARIS trial using canagliflozin and teneligliptin

Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505

06-13-2018 | Oral combination medications | Article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

05-25-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

05-18-2018 | Type 2 diabetes | Review | Article

Combination glucose-lowering therapy plans in T2DM: Case-based considerations

Blonde L, Dipp S, Cadena D. Adv Ther 2018. doi: 10.1007/s12325-018-0694-0

04-05-2018 | Oral combination medications | Review | Article

Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

03-23-2018 | Oral combination medications | Article

SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Li D et al. Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13294

10-17-2016 | Gestational diabetes | Review | Article

Pharmacological management of gestational diabetes mellitus

Bergel R et al. Curr Diab Rep 2016; 16: 118. doi: 10.1007/s11892-016-0802-y

11-10-2016 | Type 2 diabetes | Review | Article

Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with type 2 diabetes mellitus

Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6

02-03-2017 | Medications | Review | Article

Early combination therapy with oral glucose-lowering agents in type 2 diabetes

Bianchi C et al. Drugs 2017; 77: 247–264. doi: 10.1007/s40265-017-0694-4